<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="chapter-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><?noissn?><front><journal-meta><journal-id journal-id-type="publisher-id">978-3-642-40605-8</journal-id><journal-id journal-id-type="doi">10.1007/978-3-642-40605-8</journal-id><journal-id journal-id-type="nlm-ta">Viruses and the Lung</journal-id><journal-title-group><journal-title>Viruses and the Lung</journal-title><journal-subtitle>Infections and Non-Infectious Viral-Linked Lung Disorders</journal-subtitle></journal-title-group><isbn publication-format="print">978-3-642-40604-1</isbn><isbn publication-format="electronic">978-3-642-40605-8</isbn></journal-meta><article-meta><article-id pub-id-type="pmcid">7123204</article-id><article-id pub-id-type="publisher-id">16</article-id><article-id pub-id-type="doi">10.1007/978-3-642-40605-8_16</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Parvovirus</article-title></title-group><contrib-group content-type="book editors"><contrib contrib-type="editor"><name><surname>Fraire</surname><given-names>Armando E.</given-names></name><address><phone>+1508793-6148</phone><fax>+1508793-6110</fax><email>frairea@ummhc.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="editor"><name><surname>Woda</surname><given-names>Bruce A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="editor"><name><surname>Welsh</surname><given-names>Raymond M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="editor"><name><surname>Kradin</surname><given-names>Richard L.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.168645.8</institution-id><institution-id institution-id-type="ISNI">0000000107420364</institution-id><institution>Department of Pathology, </institution><institution>University of Massachusetts Medical School, </institution></institution-wrap>Worcester, Massachusetts USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.168645.8</institution-id><institution-id institution-id-type="ISNI">0000000107420364</institution-id><institution>Department of Pathology, </institution><institution>University of Massachusetts Medical School, </institution></institution-wrap>Worcester, Massachusetts USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.168645.8</institution-id><institution-id institution-id-type="ISNI">0000000107420364</institution-id><institution>Department of Pathology, </institution><institution>University of Massachusetts Medical School, </institution></institution-wrap>Worcester, Massachusetts USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.32224.35</institution-id><institution-id institution-id-type="ISNI">0000000403869924</institution-id><institution>Massachusetts General Hospital, </institution></institution-wrap>Boston, Massachusetts USA </aff></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Green</surname><given-names>Linda K.</given-names></name><degrees>M.D.</degrees><address><email>linda.green2@va.gov</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Fraire</surname><given-names>Armando E.</given-names></name><degrees>M.D.</degrees><address><email>armando.fraire@umassmemorial.org</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">000000012160926X</institution-id><institution>Department of Diagnostic and Therapeutic Care Line, </institution><institution>M.E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, </institution></institution-wrap>2002 Holcombe Blvd., Houston, TX 77030 USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.168645.8</institution-id><institution-id institution-id-type="ISNI">0000000107420364</institution-id><institution>Department of Pathology, </institution><institution>UMass Memorial Medical Center, University of Massachusetts Medical School, </institution></institution-wrap>One Innovation Drive, Worcester, MA 01605 USA </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>8</month><year>2013</year></pub-date><fpage>133</fpage><lpage>140</lpage><permissions><copyright-statement>&#x000a9; Springer-Verlag Berlin Heidelberg 2014</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p>
<italic>Name of Virus</italic>: Parvovirus</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Systemic Lupus Erythematosus</kwd><kwd>Sickle Cell Disease</kwd><kwd>Diffuse Alveolar Damage</kwd><kwd>Hereditary Spherocytosis</kwd><kwd>Scarlet Fever</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<italic>Name of Virus</italic>: Parvovirus</p><sec id="Sec1" sec-type="introduction"><title>Brief Introduction</title><p>Parvovirus (PV), one of the smallest viral pathogens, derives its name from the Latin <italic>parvum</italic>, meaning small. Discovered in 1974 by researchers studying viral hepatitis (Cossart et al. <xref ref-type="bibr" rid="CR16">1975</xref>), parvoviruses are important human and animal pathogens. The virus, an Erythrovirus propagates best within erythroid progenitor cells (Brown et al. <xref ref-type="bibr" rid="CR12">1993</xref>). In humans, the cellular receptor P antigen for parvovirus B19s may cause erythema infectiosum, an entity also called &#x0201c;fifth disease&#x0201d; (recognized in 1889 and named in 1899). Its name given to it historically as the fifth disease, after measles, rubella, varicella, and scarlet fever of the classical childhood skin rashes or exanthems in children (David <xref ref-type="bibr" rid="CR18">1982</xref>; Plummer et al. <xref ref-type="bibr" rid="CR49">1985</xref>; Brown et al. <xref ref-type="bibr" rid="CR12">1993</xref>).</p><p>Parvovirus infection is more common in children than adults. About 20 % of those infected will be asymptomatic and 50 % will experience nonspecific flu-like symptoms. PV can cause serious illnesses including pneumonia with diffuse alveolar damage resulting in acute respiratory distress syndrome, major joint arthritis, life-threatening transient aplastic crisis especially in patients with underlying sickle cell disease, and hemolytic disease such as chronic red cell aplasia in immunocompromised patients (Smith-Whitley et al. <xref ref-type="bibr" rid="CR54">2004</xref>). It may also cause early fetal death or hydrops fetalis and unrecognized viral myocarditis (Young and Brown <xref ref-type="bibr" rid="CR57">2004</xref>). Lung involvement is uncommon but has been reported to occur in children with fatal multiorgan failure (Ferraz <xref ref-type="bibr" rid="CR23">2005</xref>). Pleuropneumonitis due to PV can be seen in immunocompromised adults with heart-lung transplants (Janner et al. <xref ref-type="bibr" rid="CR29">1994</xref>; Castagna et al. <xref ref-type="bibr" rid="CR14">2011</xref>) but may also be seen in sporadic non-immunocompromised patients (Wardeh and Marik <xref ref-type="bibr" rid="CR56">1998</xref>; Morris and Smilack <xref ref-type="bibr" rid="CR45">1998</xref>). The multiplicity of clinical presentations of the infection can masquerade as other disorders, in all ages resulting in misdiagnosis and possible overtreatment.</p></sec><sec id="Sec2"><title>Synonyms</title><p>Fifth disease, Nakatani virus, Erythema infectiosum, Slapped cheek syndrome, Apple sickness, Butterfly pox</p></sec><sec id="Sec3"><title>Classification</title><p>Family &#x02013; <italic>Parvoviridae</italic>
</p><p>Genus &#x02013; <italic>Erythrovirus</italic>
</p></sec><sec id="Sec4"><title>Epidemiology</title><p>Infection by PV occurs worldwide with similar infectivity rates in the USA, Europe, and Asia (Norja et al. <xref ref-type="bibr" rid="CR48">2008</xref>). By age of 15 years, over 50 % of adolescents have antibodies from previous childhood infection (Young and Brown <xref ref-type="bibr" rid="CR57">2004</xref>). The number of people infected over adulthood increases so that the majority of elderly individuals are seropositive (Kerr <xref ref-type="bibr" rid="CR33">1996</xref>). Studies of fifth disease outbreaks in the UK have shown that many children, and adults had evidence of PV antibodies but not the symptoms of the disease (Anderson et al. <xref ref-type="bibr" rid="CR2">1983</xref>). In temperate climates, infections peak in late winter or early spring with sporadic small epidemics (Cohen and Buckley <xref ref-type="bibr" rid="CR15">1988</xref>). PV B19 spreads through respiratory droplets and is highly contagious (Anderson et al. <xref ref-type="bibr" rid="CR3">1985</xref>). Household transmission is &#x0003e;50 % and 20&#x02013;30 % for teachers and day-care providers. As it lacks a lipid envelope and has high genomic stability, the PV is difficult to kill and is resistant to heat and solvent detergents (Kaufmann et al. <xref ref-type="bibr" rid="CR32">2004</xref>). PV infection has been reported as a nosocomial infection with transmission via blood products (especially pooled factors VIII and IX) and in health-care workers from patients and contaminated specimens (Kooistra et al. <xref ref-type="bibr" rid="CR37">2011</xref>) (Seng et al. <xref ref-type="bibr" rid="CR51">1994</xref>) (Siegl and Cassinotti <xref ref-type="bibr" rid="CR53">1998</xref>). PV is transmitted vertically from infected mothers to fetuses with a 30 % risk of transplacental transmission. PVB19 is the predominant pathogen and is the prototype strain for genotype 1 (Failey et al. <xref ref-type="bibr" rid="CR22">1995</xref>; Jordan et al. <xref ref-type="bibr" rid="CR30">2001</xref>). Less common, recently discovered erythroviruses (genotypes 2 and 3) are increasing and spreading. Genotypes 1 and 2 are typically present in Western countries (the USA and Europe) and genotype 3 in sub-Saharan Africa and South America (Freitas et al. <xref ref-type="bibr" rid="CR24">2008</xref>).</p></sec><sec id="Sec5"><title>Ultrastructure</title><p>Parvovirus B19 is a 26 nm, non-enveloped 5.6 kb single-stranded DNA virus. The capsid consists of two structural proteins (VP1 and VP2) which arise from alternative splicing, therefore VP1 and VP 2 are similar except VP2 contains an additional 226 amino acids. In addition, PV has one nonstructural protein (NSI). Importantly PV has P blood group antigen cellular receptor (globoside) (Heegaard and Brown <xref ref-type="bibr" rid="CR26">2002</xref>). The translation machinery of PV is all in the cytoplasm, and then the proteins home back in the nucleus for viral assembly.</p></sec><sec id="Sec6"><title>Immunology</title><p>Parvovirus is demonstratable in the bloodstream some 7&#x02013;10 days after exposure and persists for approximately 5 days with viral loads exceeding 10<sup>12</sup> particles/ml of blood. Parvovirus B19-specific IgM antibodies are at a detectable range within 10&#x02013;12 days and persist for about 3&#x02013;5 months. IgG antibodies are seen 15 days postinfection and can persist for long periods. Usually, the patient will have lifelong immunity (De Haan et al. <xref ref-type="bibr" rid="CR19">2007</xref>). An effective immune response is only seen if VP1 antibodies are present. Isa et al. have shown a cell-mediated immune response with production of interferon (IFN)-gamma, interleukin (IL)-2, IL-6, and tumor necrosis factor (TNF)-alpha (Isa et al. <xref ref-type="bibr" rid="CR28">2007</xref>).</p></sec><sec id="Sec7"><title>Clinical Features</title><p>A relatively small percent of patients (25 %) may be infected but remain totally asymptomatic. However, asymptomatic patients are still capable of spreading the disease. In about 75 % of non-immunocompromised patients that exhibit symptoms, there are symptoms of an upper respiratory infection or flu-like illness with fever, runny nose, nausea, and headache (Mandel <xref ref-type="bibr" rid="CR42">2009</xref>). After several days, some patients (up to 25 %) develop a red rash on their face which is felt to be related to the formation and deposition of immune complexes (Young and Brown <xref ref-type="bibr" rid="CR57">2004</xref>). After several days, the rash may spread and may then appear on the chest, back, buttocks, and extremities. On the soles of the feet, the rash may be especially pruritic (Sharad and Kapur <xref ref-type="bibr" rid="CR52">2005</xref>). The rash clears in a week or two, and when it begins to resolve, it may appear &#x0201c;lacy&#x0201d; in appearance. The rash may be very &#x0201c;fleeting&#x0201d; (&#x0003c;24 h), but recurrences may be induced by exposure to sunlight, heat, emotion, or strenuous exercise. Older infected children may also have lymphadenopathy and an atypical rash (Broliden et al. <xref ref-type="bibr" rid="CR11">2006</xref>).</p><p>In adults, especially middle-aged women, joint pain and swelling (immune-mediated polyarthropathy) may appear involving the joints of the hands, feet, or knees (Moore <xref ref-type="bibr" rid="CR43">2000</xref>). Joint symptoms can be seen in 8 % of children and 60 % of infected adults. This may be the only manifestation of the infection in these patients. The inflammatory joint symptoms may persist for weeks to months but usually resolve without long-term damage (Tello-Winniczuk et al. <xref ref-type="bibr" rid="CR55">2011</xref>; Naides et al. <xref ref-type="bibr" rid="CR47">1990</xref>; Kerr et al. <xref ref-type="bibr" rid="CR34">1995</xref>). There have been scattered reported cases of fibromyalgia symptoms linked to PVB19 via IgM serology (Buyukkose et al. <xref ref-type="bibr" rid="CR13">2009</xref>). A causal relationship with fibromyalgia is uncertain as the PV infection may be incidental, in some cases.</p><p>PVB19 affects 1&#x02013;5 % of pregnant women with most women having a normal pregnancy outcome (Ergaz and Ornoy <xref ref-type="bibr" rid="CR21">2006</xref>). There are documented relationships with fetal deaths secondary to possible fetal anemia with resultant fetal high-output cardiac failure and nonimmune hydrops fetalis (Adler and Koch <xref ref-type="bibr" rid="CR1">2011</xref>). Intrauterine PVB19 has an affinity for the P antigen expressed on fetal cardiac myocytes leading to cardiac failure from direct or indirect or autoimmune damage (Bowles et al <xref ref-type="bibr" rid="CR9">2003</xref>). There have been isolations of PVB19 in children and adults with unexplained fulminant hepatitis. These patients had a low bilirubin level, no jaundice, and recovered rapidly. Serum high values of AST and ALT normalized in 3 weeks (Huang et al. <xref ref-type="bibr" rid="CR27">2012</xref>).</p><p>The most recognized serious disease associated with PVB19 is aplastic crisis which may be life threatening. In patients with increased red blood cell (RBC) turnover from other disorders such as (sickle cell disease, hereditary spherocytosis), PV infection can result in an abrupt cessation of RBC production due to infection of erythroid progenitor cells in the bone marrow. This may result in severe anemia with congestive heart failure or stroke. Patients may also develop pancytopenia with thrombocytopenia. With clearance of the virus, the crisis will abate. In patients who are immunocompromised, the lack of immunity results in persistent infection and chronic pure red cell aplasia (Posfay-Barbe and Michaels <xref ref-type="bibr" rid="CR50">2003</xref>). PVB19-associated pure red cell aplasia has been the first presentation for HIV-infected patients (Koduri <xref ref-type="bibr" rid="CR36">2000</xref>).</p><p>In rare cases of PV-related fulminant pulmonary failure, patients may present with a sudden onset of respiratory distress (Ferraz et al. <xref ref-type="bibr" rid="CR23">2005</xref>). Bronchoscopy may only reveal mild mucosal erythema with mild increase in secretions. Diffuse bilateral parenchymal opacities with or without effusions can be seen on chest radiography (Berjaoui et al. <xref ref-type="bibr" rid="CR5">2006</xref>). Other PV symptoms may or may not be seen including rash, arthropathy, and transient anemia symptoms. In patients receiving stem cell transplant, PV B19 pneumonia may be misdiagnosed as another viral or opportunistic infection, and serology screening is imperative in order to avoid missing acute infection.</p></sec><sec id="Sec8"><title>Pathologic Changes</title><p>Skin lesions when biopsied to exclude other diseases usually have a nonspecific histologic picture (Katta <xref ref-type="bibr" rid="CR31">2002</xref>). There may be interstitial histiocytic infiltrates with piecemeal fragmentation of collagen and a mononuclear cell-predominant vascular injury pattern. Other features include an interface dermatitis, eczematous alterations, and papillary dermal edema (Bonvivini et al. <xref ref-type="bibr" rid="CR8">2010</xref>). The pathology of cutaneous B19 infection suggests tissue injury mediated by delayed-type hypersensitivity, by antibody-dependent cellular immunity directed at microbial antigenic targets in the epidermis and endothelium, and by circulating immune complexes in the setting of leukocytoclastic vasculitis (Magro et al. <xref ref-type="bibr" rid="CR40">2000</xref>). In patients with transient aplastic crisis, the bone marrow will have erythroid hypoplasia and occasional giant erythroblasts and may rarely have proerythoid cells with intranuclear viral inclusions (Crook et al. <xref ref-type="bibr" rid="CR17">2000</xref>). In infected fetuses, there are many erythroid precursor cells with eosinophilic inclusions which compress the nuclear chromatin against the nuclear membrane in the placenta and fetal tissues (Morey et al. <xref ref-type="bibr" rid="CR44">1992</xref>).</p><p>In patients with pulmonary manifestations, bronchioloalveolar lavage at bronchoscopy may show a lymphocyte-rich effusion. Such effusions may also be seen in autoimmune diseases and viral pneumonias. Desquamated balls of reactive type II pneumocytes may be abundant with large nuclei with increased nuclear to cytoplasmic ratios, prominent clumped chromatin and large round to irregular nucleoli, and eosinophilic inclusions (Fig. <xref rid="Fig1" ref-type="fig">16.1</xref>). The lungs may show classic changes of diffuse alveolar damage with hyaline membranes, reactive type II pneumocytes, and lymphocytic infiltrates (Beske et al <xref ref-type="bibr" rid="CR7">2007</xref>). In acute presentations, the lungs may show intra-alveolar hemorrhage due to weakened and damaged intraseptal capillaries. Viral inclusions are extremely difficult to find except in rare patients who are immunocompromised. Immunohistochemistry is however helpful highlighting infected cells (Fig. <xref rid="Fig2" ref-type="fig">16.2</xref>). The diagnosis is based on serological rise of PV IgM and DNA evidence of PV from lung biopsy or cytologic specimens (Berjaoui et al. <xref ref-type="bibr" rid="CR5">2006</xref>). The exact pathogenesis of severe pulmonary complications by B19 is not understood but may be related to a cytotoxic effect of the virus directly or indirectly on the interstitial endothelial cells. An aberrant host immune response triggered by B19 may also contribute to the pulmonary pathology (Magro et al. <xref ref-type="bibr" rid="CR41">2006</xref>). The lung tissues are not the preferred site for virus replication in humans or other mammals. This is why PV B19 pneumonia is very rare or unrecognized. B19 DNA may persist perpetually in human tissues such as skin, synovial cells, and hepatocytes. The significance of a positive PCR for PV B19 may be related to the amount observed. Since it may be harbored in healthy tissues, PCR detection of PV B19 during an illness may not be definitive proof that PV is the cause of the lung injury unless other causes are excluded. In immunocompromised patients with PV B19 pneumonia, it is difficult to determine if it is a new infection associated with viremia or a reactivation of virus dormant within the lung tissues. In fact, simultaneous infection with two pathogens often results in enhanced morbidity and mortality, in particular in immunocompromised patients (Broliden <xref ref-type="bibr" rid="CR10">2001</xref>).
<fig id="Fig1"><label>Fig. 16.1</label><caption><p>Parvovirus infections in the lung are similar to those shown in other organs. This illustration shows the bone marrow of an immunocompromised patient. Note eosinophilic inclusions within early erythroid forms. Hematoxylin and eosin (Courtesy of Dr. Richard L. Kradin, Massachusetts General Hospital, with permission from Diagnostic Pathology of Infectious Disease, 2010, Saunders-Elsevier, Publishers)</p></caption><graphic xlink:href="272508_1_En_16_Fig1_HTML" id="MO1"/></fig>
<fig id="Fig2"><label>Fig. 16.2</label><caption><p>Immunohistochemical stain for parvovirus highlights viral inclusions and confirms the diagnosis. Immunoperoxidase (Courtesy of Dr. Richard L. Kradin, Massachusetts General Hospital, with permission from Diagnostic Pathology of Infectious Disease, 2010, Saunders-Elsevier, Publishers)</p></caption><graphic xlink:href="272508_1_En_16_Fig2_HTML" id="MO2"/></fig>
</p></sec><sec id="Sec9"><title>Diagnosis</title><p>In immunocompetent patients, the diagnosis is based on the presence of IgM antibodies (Knipe and Howley <xref ref-type="bibr" rid="CR35">2007</xref>). The presence of IgG alone may only suggest previous infection. The virus can be detected by the polymerase chain reaction (PCR) assay for months to years after infection. There may be a transient drop in the reticulocyte count and hemoglobulin concentration in week 1 or 2, but the numbers normalize after a month (Doyle et al. <xref ref-type="bibr" rid="CR20">2000</xref>).</p><p>In acute lung involvement, the diagnosis may be easily missed and misinterpreted as vasculitis or an autoimmune disease or another etiology. Suspicion is needed to determine if PV is the cause of the respiratory failure using serology and DNA evidence of PV infection. This may be difficult because IgM may be persistent from a previous self-limited infection and PV DNA can persist for months. PV is a very prevalent disease in the general population and has been demonstrated in several types of lung damage patterns thought to possibly be related to the ANCA-positive vasculitic syndromes associated with PV. PV has also been reported in idiopathic interstitial pulmonary fibrosis and may be related to capillary damage. PV has a known affinity for capillary endothelium (Magro et al. <xref ref-type="bibr" rid="CR41">2006</xref>).</p></sec><sec id="Sec10"><title>Differential Diagnosis</title><p>PV symptoms prior to the appearance of the rash are nonspecific and thought to represent influenza or a rhinoviral infection. If the rash appears, in children it can be mistaken for rubella. The polyarthropathy can be confused with rheumatoid arthritis especially since patients may have a transient increase in serum rheumatoid factor (Tello-Winniczuk et al. <xref ref-type="bibr" rid="CR55">2011</xref>).</p><p>PVB19 can be misdiagnosed as Systemic Lupus Erythematosus (SLE). In an initial presentation of a patient, the symptoms of PVB19 may overlap greatly with SLE. Both PVB19 and SLE patients may have cytopenia, anti-DNA antibodies, antinuclear antibodies (ANA), and hypocomplementemia. However, patients with PVB19 will have symptom resolution in several weeks. There may be an increase of infections with PVB19 in patients with known SLE due to intrinsic immunosuppression or immunosuppressive therapies, with lower levels of circulating PV IgM and IgG (Bengtsson et al. <xref ref-type="bibr" rid="CR4">2000</xref>). In the lung, the changes may be similar to collagen vascular diseases, infections due to other viruses, and even lepidic adenocarcinoma. The differential diagnosis includes many entities which may cause acute respiratory distress syndrome. The transient or rapid anemia with or without skin rash can help in recognizing the infection. Because PV can create an environment with lower resistance to other opportunistic pathogens, a concurrent fungal or bacterial pneumonia may overshadow the effects of PV B19.</p></sec><sec id="Sec11"><title>Prevention</title><p>Prevention of acute illness is often difficult. When outbreaks are recognized, decrease of exposure to body fluids of the infected patient is useful. Recognized viral illness with fevers and rashes in children should result in their removal from the day-care or school environment (Leppard et al. <xref ref-type="bibr" rid="CR39">2007</xref>). Disinfection is not always effective due to the hardiness of the virus. The US Food and Drug Administration (FDA) issued a recommendation in July 2009 that makers of plasma-derived products (which include plasma-derived factor VIII and factor IX concentrates) begin screening for human PVB19 by performing nucleic acid testing.</p></sec><sec id="Sec12"><title>Treatment and Outcome</title><p>Treatment is symptomatic in most cases. Other treatments related to the varied clinical symptoms may include blood transfusions for aplastic crisis or intrauterine infections. Intravenous immunoglobulin may be used in immunocompromised patients or in placental exchanges of infected pregnant women with fetal distress (Kurtzman et al. <xref ref-type="bibr" rid="CR38">1989</xref>; Mouthon et al. <xref ref-type="bibr" rid="CR46">2005</xref>). Antiretroviral therapies are important in HIV patients to prevent aplastic crisis. In patients with lung involvement, early recognition is needed for provided pulmonary support, antiviral therapies, and antibiotics to prevent secondary bacterial infections which may result in sepsis and demise. Despite these measures, the disease may be fatal, especially if the patient is immunocompromised.</p></sec><sec id="Sec13"><title>Vaccination</title><p>Effective vaccines are available for animal strains of PV, but currently, there is no approved vaccine available for humans. There is progress for their development and use in young children. Technology to express viral proteins VP1 and VP2, derived from a copy of the parvovirus B-19 genome (strain Au) obtained from a child with sickle cell disease and transient aplastic crisis, was developed at the National Heart, Lung, and Blood Institute. Individual viral proteins were expressed in a baculovirus system and, when recombinant vectors are cotransfected into insect cells, VP1 and VP2 spontaneously assemble into empty viral-like particles. The vaccine consists of two viral proteins (VP1 and VP2) in separate baculovirus vectors that are coinfected at the correct multiplicity of infections (MOIs) into Spodoptera frugiperda (Sf9) cells and that, upon expression, self-assemble into immunogenic viruslike particles. Phase 1 trials have been completed, but mass production is needed for testing (Bernstein et al. <xref ref-type="bibr" rid="CR6">2011</xref>).</p></sec><sec id="Sec14"><title>Clinicopathologic Capsule</title><p>A common childhood disease which is often unrecognized, parvovirus infection causes an influenza-like illness which can be associated with a rash known as erythema infectiosum (fifth disease). Ultrastructurally, the viral agent, a member of the family Parvoviridae, is a small single-stranded DNA virus that uniquely infects human erythroid progenitor cells. The clinical presentations may vary from irritative (upper respiratory infections and rashes) to severe (diffuse alveolar damage with ARDS, arthropathy, cardiomyopathy, fulminant hepatitis, hydrops fetalis, and aplastic crisis). A definitive diagnosis can be made with detection of IgM by serology and specific PVB19 DNA PCR. A previous infection results in lifelong immunity unless the patient is immunocompromised.</p></sec></body><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>SP</given-names></name><name><surname>Koch</surname><given-names>WC</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Remington</surname><given-names>J</given-names></name></person-group><article-title>Human parvovirus</article-title><source>Infectious diseases of the fetus and newborn</source><year>2011</year><edition>7</edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>Saunders</publisher-name></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>MJ</given-names></name><name><surname>Higgins</surname><given-names>PG</given-names></name><name><surname>Davis</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Human parvovirus, the cause of erythema infectiosum (fifth disease)?</article-title><source>Lancet</source><year>1983</year><volume>1</volume><fpage>1378</fpage></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>MJ</given-names></name><name><surname>Higgins</surname><given-names>PG</given-names></name><name><surname>Davis</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Experimental parvovirus infection in humans</article-title><source>J Infect Dis</source><year>1985</year><volume>152</volume><issue>2</issue><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1093/infdis/152.2.257</pub-id><?supplied-pmid 2993431?><pub-id pub-id-type="pmid">2993431</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengtsson</surname><given-names>A</given-names></name><name><surname>Widell</surname><given-names>A</given-names></name><name><surname>Elmstahl</surname><given-names>S</given-names></name><etal/></person-group><article-title>No serological indications that systemic lupus erythematosus is linked with seroexposure to human parvovirus B19</article-title><source>Ann Rheum Dis</source><year>2000</year><volume>59</volume><fpage>64</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1136/ard.59.1.64</pub-id><?supplied-pmid 10627430?><pub-id pub-id-type="pmid">10627430</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berjaoui</surname><given-names>W</given-names></name><name><surname>Dean</surname><given-names>N</given-names></name><name><surname>Dahle</surname><given-names>N</given-names></name></person-group><article-title>Proteinuria, pancytopenia ad hypoxaemic respiratory failure in a 28-year-old female</article-title><source>Eur Respir J</source><year>2006</year><volume>28</volume><issue>2</issue><fpage>452</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1183/09031936.06.00003106</pub-id><?supplied-pmid 16880374?><pub-id pub-id-type="pmid">16880374</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>DI</given-names></name><name><surname>El-Sahly</surname><given-names>HM</given-names></name><name><surname>Keitel</surname><given-names>WA</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a candidate parvovirus B19 vaccine</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>43</issue><fpage>7357</fpage><lpage>7363</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.080</pub-id><?supplied-pmid 21807052?><pub-id pub-id-type="pmid">21807052</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beske</surname><given-names>F</given-names></name><name><surname>Modrow</surname><given-names>S</given-names></name><name><surname>S&#x000f6;rensen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation</article-title><source>Bone Marrow Transplant</source><year>2007</year><volume>40</volume><fpage>89</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/sj.bmt.1705693</pub-id><?supplied-pmid 17468770?><pub-id pub-id-type="pmid">17468770</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonvivini</surname><given-names>F</given-names></name><name><surname>La Placa</surname><given-names>M</given-names></name><name><surname>Manaresi</surname><given-names>E</given-names></name><etal/></person-group><source>Dermatology</source><year>2010</year><volume>220</volume><fpage>138</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1159/000277431</pub-id><pub-id pub-id-type="pmid">20110633</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowles</surname><given-names>NE</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Kearney</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Detection of viruses in myocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of myocarditis in children and adults</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>42</volume><fpage>466</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(03)00648-X</pub-id><?supplied-pmid 12906974?><pub-id pub-id-type="pmid">12906974</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broliden</surname><given-names>K</given-names></name></person-group><article-title>Parvovirus B19 infection in pediatric solid-organ and bone marrow transplantation</article-title><source>Pediatr Transplant</source><year>2001</year><volume>5</volume><fpage>320</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1034/j.1399-3046.2001.00035.x</pub-id><?supplied-pmid 11560750?><pub-id pub-id-type="pmid">11560750</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broliden</surname><given-names>K</given-names></name><name><surname>Tolfvenstam</surname><given-names>T</given-names></name><name><surname>Norbeck</surname><given-names>O</given-names></name></person-group><article-title>Clinical aspects of parvovirus B19 infection</article-title><source>J Intern Med</source><year>2006</year><volume>260</volume><fpage>285</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2006.01697.x</pub-id><?supplied-pmid 16961667?><pub-id pub-id-type="pmid">16961667</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>KE</given-names></name><name><surname>Hibbs</surname><given-names>JR</given-names></name><name><surname>Gallinella</surname><given-names>G</given-names></name><etal/></person-group><article-title>Erythrocyte P antigen: cellular receptor for B19 parvovirus</article-title><source>Science</source><year>1993</year><volume>262</volume><fpage>114</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1126/science.8211117</pub-id><?supplied-pmid 8211117?><pub-id pub-id-type="pmid">8211117</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buyukkose</surname><given-names>M</given-names></name><name><surname>Kozanoglu</surname><given-names>E</given-names></name><name><surname>Basaran</surname><given-names>S</given-names></name><etal/></person-group><article-title>Seroprevalence of parvovirus B19 in fibromyalgia syndrome</article-title><source>Clin Rheumatol</source><year>2009</year><volume>28</volume><fpage>305</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1007/s10067-008-1044-4</pub-id><?supplied-pmid 19057847?><pub-id pub-id-type="pmid">19057847</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castagna</surname><given-names>L</given-names></name><name><surname>Furst</surname><given-names>S</given-names></name><name><surname>El-Cheikh</surname><given-names>J</given-names></name><etal/></person-group><article-title>Parvovirus B19 as an etiological agent of acute pleuro-pericarditis</article-title><source>Bone Marrow Transplant</source><year>2011</year><volume>46</volume><fpage>317</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1038/bmt.2010.103</pub-id><?supplied-pmid 20421866?><pub-id pub-id-type="pmid">20421866</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>B</given-names></name><name><surname>Buckley</surname><given-names>M</given-names></name></person-group><article-title>The prevalence of antibody to human parvovirus B19 in England and Wales</article-title><source>J Med Microbiol</source><year>1988</year><volume>25</volume><fpage>151</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1099/00222615-25-2-151</pub-id><?supplied-pmid 3339634?><pub-id pub-id-type="pmid">3339634</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cossart</surname><given-names>YE</given-names></name><name><surname>Field</surname><given-names>AM</given-names></name><name><surname>Cant</surname><given-names>B</given-names></name><etal/></person-group><article-title>Parvo-like particles in human sera</article-title><source>Lancet</source><year>1975</year><volume>1</volume><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(75)91074-0</pub-id><?supplied-pmid 46024?><pub-id pub-id-type="pmid">46024</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crook</surname><given-names>T</given-names></name><name><surname>Rogers</surname><given-names>B</given-names></name><name><surname>McFarland</surname><given-names>R</given-names></name><etal/></person-group><article-title>Unusual bone marrow manifestations of parvovirus B19 infection in immunocompromised patients</article-title><source>Hum Pathol</source><year>2000</year><volume>31</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/S0046-8177(00)80215-4</pub-id><?supplied-pmid 10685629?><pub-id pub-id-type="pmid">10685629</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>M</given-names></name></person-group><article-title>Fifth disease: still hazy after all these years</article-title><source>JAMA</source><year>1982</year><volume>248</volume><fpage>553</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1001/jama.1982.03330110078039</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haan</surname><given-names>TR</given-names></name><name><surname>Beersma</surname><given-names>MF</given-names></name><name><surname>Oepkes</surname><given-names>D</given-names></name><etal/></person-group><article-title>Parvovirus B19 infection in pregnancy: maternal and fetal viral load measurements related to clinical parameters</article-title><source>Prenat Diagn</source><year>2007</year><volume>27</volume><fpage>46</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17154332</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname><given-names>S</given-names></name><name><surname>Kerr</surname><given-names>S</given-names></name><name><surname>O&#x02019;Keeffe</surname><given-names>G</given-names></name><etal/></person-group><article-title>Detection of parvovirus B19 IgM by antibody capture enzyme immunoassay: receiver operating characteristic analysis</article-title><source>J Virol Methods</source><year>2000</year><volume>90</volume><fpage>143</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/S0166-0934(00)00227-5</pub-id><?supplied-pmid 11064115?><pub-id pub-id-type="pmid">11064115</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ergaz</surname><given-names>Z</given-names></name><name><surname>Ornoy</surname><given-names>A</given-names></name></person-group><article-title>Parvovirus B19 in pregnancy</article-title><source>Reprod Toxicol</source><year>2006</year><volume>21</volume><fpage>421</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/j.reprotox.2005.01.006</pub-id><?supplied-pmid 16580942?><pub-id pub-id-type="pmid">16580942</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Failey</surname><given-names>CK</given-names></name><name><surname>Smoleniec</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B 19 infection</article-title><source>Lancet</source><year>1995</year><volume>346</volume><fpage>1335</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(95)92346-2</pub-id><pub-id pub-id-type="pmid">7475774</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferraz</surname><given-names>C</given-names></name><name><surname>Cunha</surname><given-names>F</given-names></name><name><surname>Mota</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Acute respiratory distress syndrome in a child with human parvovirus B19 infection</article-title><source>Pediatr Infect Dis J</source><year>2005</year><volume>24</volume><fpage>1009</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1097/01.inf.0000183768.84890.ae</pub-id><?supplied-pmid 16282940?><pub-id pub-id-type="pmid">16282940</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freitas</surname><given-names>R</given-names></name><name><surname>Melo</surname><given-names>F</given-names></name><name><surname>Oliveira</surname><given-names>D</given-names></name><etal/></person-group><article-title>Molecular characterization of human erythrovirus B19 stains obtained from patients with several clinical presentations in the Amazon region of Brazil</article-title><source>J Clin Virol</source><year>2008</year><volume>43</volume><fpage>60</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2008.03.033</pub-id><?supplied-pmid 18502682?><pub-id pub-id-type="pmid">18502682</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heegaard</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name></person-group><article-title>Human parvovirus B19</article-title><source>Clin Microbiol Rev</source><year>2002</year><volume>15</volume><fpage>485</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1128/CMR.15.3.485-505.2002</pub-id><?supplied-pmid 12097253?><pub-id pub-id-type="pmid">12097253</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>RJ</given-names></name><name><surname>Varr</surname><given-names>BC</given-names></name><name><surname>Tiadafilopoulos</surname><given-names>G</given-names></name></person-group><article-title>Acute fulminant hepatic failure associated with parvovirus B19 infection in an immunocompetent adult</article-title><source>Dig Dis Sci</source><year>2012</year><volume>57</volume><issue>11</issue><fpage>2811</fpage><lpage>2813</lpage><pub-id pub-id-type="pmid">22395961</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isa</surname><given-names>A</given-names></name><name><surname>Lundqvist</surname><given-names>A</given-names></name><name><surname>Lindblom</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cytokine responses in acute and persistent human parvovirus B19 infection</article-title><source>Clin Exp Immunol</source><year>2007</year><volume>147</volume><fpage>419</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2006.03286.x</pub-id><?supplied-pmid 17302890?><pub-id pub-id-type="pmid">17302890</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janner</surname><given-names>D</given-names></name><name><surname>Bork</surname><given-names>J</given-names></name><name><surname>Baum</surname><given-names>M</given-names></name><etal/></person-group><article-title>Severe pneumonia after heart transplantation as a result of human parvovirus B19</article-title><source>Heart Lung Transplant</source><year>1994</year><volume>13</volume><fpage>336</fpage><lpage>338</lpage></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>JA</given-names></name><name><surname>Huff</surname><given-names>D</given-names></name><name><surname>DeLoia</surname><given-names>JA</given-names></name></person-group><article-title>Placental cellular immune response in women infected with human parvovirus B19 during pregnancy</article-title><source>Clin Diagn Lab Immunol</source><year>2001</year><volume>8</volume><fpage>288</fpage><lpage>292</lpage><?supplied-pmid 11238210?><pub-id pub-id-type="pmid">11238210</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katta</surname><given-names>R</given-names></name></person-group><article-title>Parvovirus B19: a review</article-title><source>Dermatol Clin</source><year>2002</year><volume>20</volume><fpage>333</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/S0733-8635(01)00013-4</pub-id><?supplied-pmid 12120446?><pub-id pub-id-type="pmid">12120446</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>B</given-names></name><name><surname>Simpson</surname><given-names>AA</given-names></name><name><surname>Rossmann</surname><given-names>MG</given-names></name></person-group><article-title>The structure of human parvovirus B19</article-title><source>Proc Natl Acad Sci</source><year>2004</year><volume>101</volume><fpage>11628</fpage><lpage>11633</lpage><pub-id pub-id-type="doi">10.1073/pnas.0402992101</pub-id><?supplied-pmid 15289612?><pub-id pub-id-type="pmid">15289612</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>JR</given-names></name></person-group><article-title>Parvovirus B19 infection</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>1996</year><volume>15</volume><fpage>10</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1007/BF01586181</pub-id><?supplied-pmid 8641299?><pub-id pub-id-type="pmid">8641299</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>J</given-names></name><name><surname>Carton</surname><given-names>J</given-names></name><name><surname>Curran</surname><given-names>M</given-names></name><etal/></person-group><article-title>A study of the role of parvovirus B19 in rheumatoid arthritis</article-title><source>Br J Rheumatol</source><year>1995</year><volume>34</volume><fpage>809</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/34.9.809</pub-id><?supplied-pmid 7582718?><pub-id pub-id-type="pmid">7582718</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Knipe</surname><given-names>D</given-names></name><name><surname>Howley</surname><given-names>P</given-names></name></person-group><source>Fields virology</source><year>2007</year><edition>5</edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koduri</surname><given-names>PR</given-names></name></person-group><article-title>Parvovirus B19-related anemia in HIV-infected patients</article-title><source>AIDS Patient Care STDS</source><year>2000</year><volume>14</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1089/108729100318082</pub-id><?supplied-pmid 12240888?><pub-id pub-id-type="pmid">12240888</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kooistra</surname><given-names>K</given-names></name><name><surname>Mesman</surname><given-names>HJ</given-names></name><name><surname>de Waal</surname><given-names>M</given-names></name><etal/></person-group><article-title>Epidemiology of high-level parvovirus B19 viraemia among Dutch blood donors, 2003&#x02013;2009</article-title><source>Vox Sang</source><year>2011</year><volume>100</volume><fpage>261</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1111/j.1423-0410.2010.01423.x</pub-id><?supplied-pmid 20946549?><pub-id pub-id-type="pmid">20946549</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtzman</surname><given-names>G</given-names></name><name><surname>Frickhofen</surname><given-names>N</given-names></name><name><surname>Kimball</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pure red-cell aplasia of 10 years&#x02019; duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy</article-title><source>N Engl J Med</source><year>1989</year><volume>321</volume><fpage>519</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1056/NEJM198908243210807</pub-id><?supplied-pmid 2548098?><pub-id pub-id-type="pmid">2548098</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Leppard</surname><given-names>K</given-names></name><name><surname>Nigel</surname><given-names>D</given-names></name><name><surname>Easton</surname><given-names>A</given-names></name></person-group><source>Introduction to modern virology</source><year>2007</year><publisher-loc>London</publisher-loc><publisher-name>Blackwell</publisher-name></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magro</surname><given-names>C</given-names></name><name><surname>Dawood</surname><given-names>M</given-names></name><name><surname>Crowson</surname><given-names>A</given-names></name></person-group><article-title>The cutaneous manifestations of human parvovirus B19 infection</article-title><source>Hum Pathol</source><year>2000</year><volume>31</volume><fpage>488</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1053/hp.2000.6714</pub-id><?supplied-pmid 10821497?><pub-id pub-id-type="pmid">10821497</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magro</surname><given-names>CM</given-names></name><name><surname>Wusirika</surname><given-names>R</given-names></name><name><surname>Frambach</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Autoimmune-like pulmonary disease in association with parvovirus B19: a clinical, morphologic and molecular study in 12 cases</article-title><source>Appl Immunohistochem Mol Morphol</source><year>2006</year><volume>14</volume><fpage>208</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1097/01.pai.0000160730.54062.6d</pub-id><?supplied-pmid 16785792?><pub-id pub-id-type="pmid">16785792</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandel</surname><given-names>E</given-names></name></person-group><article-title>Erythema infectiosum: recognizing the many faces of fifth disease</article-title><source>JAAPA</source><year>2009</year><volume>22</volume><fpage>42</fpage><lpage>46</lpage><?supplied-pmid 19601449?><pub-id pub-id-type="pmid">19601449</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>TL</given-names></name></person-group><article-title>Parvovirus-associated arthritis</article-title><source>Curr Opin Rheumatol</source><year>2000</year><volume>12</volume><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1097/00002281-200007000-00010</pub-id><?supplied-pmid 10910181?><pub-id pub-id-type="pmid">10910181</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morey</surname><given-names>A</given-names></name><name><surname>Keeling</surname><given-names>J</given-names></name><name><surname>Porter</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clinical and histopathological features of parvovirus B19 infection in the human fetus</article-title><source>Br J Obstet Gynaecol</source><year>1992</year><volume>99</volume><fpage>566</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1111/j.1471-0528.1992.tb13822.x</pub-id><?supplied-pmid 1525097?><pub-id pub-id-type="pmid">1525097</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>CN</given-names></name><name><surname>Smilack</surname><given-names>JD</given-names></name></person-group><article-title>Parvovirus B19 infection associated with respiratory distress</article-title><source>Clin Infect Dis</source><year>1998</year><volume>27</volume><fpage>900</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1086/517164</pub-id><?supplied-pmid 9798055?><pub-id pub-id-type="pmid">9798055</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouthon</surname><given-names>L</given-names></name><name><surname>Guillevin</surname><given-names>L</given-names></name><name><surname>Tellier</surname><given-names>Z</given-names></name></person-group><article-title>Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia</article-title><source>Autoimmun Rev</source><year>2005</year><volume>4</volume><fpage>264</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2004.10.004</pub-id><?supplied-pmid 15990072?><pub-id pub-id-type="pmid">15990072</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naides</surname><given-names>S</given-names></name><name><surname>Scharosch</surname><given-names>L</given-names></name><name><surname>Foto</surname><given-names>F</given-names></name><etal/></person-group><article-title>Rheumatologic manifestations of human parvovirus B19 infection in adults</article-title><source>Arthritis Rheum</source><year>1990</year><volume>33</volume><fpage>1297</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1002/art.1780330901</pub-id><?supplied-pmid 2169746?><pub-id pub-id-type="pmid">2169746</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norja</surname><given-names>P</given-names></name><name><surname>Eis-Hubinger</surname><given-names>AM</given-names></name><name><surname>Soderlund-Venermo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Rapid sequence change and geographic spread of human parvovirus B19: comparison of B19 virus evolution in acute and persistent infections</article-title><source>J Virol</source><year>2008</year><volume>82</volume><fpage>6427</fpage><lpage>6433</lpage><pub-id pub-id-type="doi">10.1128/JVI.00471-08</pub-id><?supplied-pmid 18417586?><pub-id pub-id-type="pmid">18417586</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plummer</surname><given-names>A</given-names></name><name><surname>Hammond</surname><given-names>W</given-names></name><name><surname>Forward</surname><given-names>K</given-names></name><etal/></person-group><article-title>An erythema infectiosum&#x02013;like illness caused by human parvovirus infection</article-title><source>N Engl J Med</source><year>1985</year><volume>313</volume><fpage>74</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1056/NEJM198507113130203</pub-id><?supplied-pmid 2987695?><pub-id pub-id-type="pmid">2987695</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posfay-Barbe</surname><given-names>K</given-names></name><name><surname>Michaels</surname><given-names>M</given-names></name></person-group><article-title>Parvovirus B19 in organ transplant recipients</article-title><source>Curr Opin Organ Transpl</source><year>2003</year><volume>8</volume><fpage>283</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1097/00075200-200312000-00005</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seng</surname><given-names>C</given-names></name><name><surname>Watkins</surname><given-names>P</given-names></name><name><surname>Morse</surname><given-names>D</given-names></name><etal/></person-group><article-title>Parvovirus B19 outbreak on an adult ward</article-title><source>Epidemiol Infect</source><year>1994</year><volume>113</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1017/S0950268800051773</pub-id><?supplied-pmid 7925671?><pub-id pub-id-type="pmid">7925671</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharad</surname><given-names>S</given-names></name><name><surname>Kapur</surname><given-names>S</given-names></name></person-group><article-title>Emerging human infections: an overview of parvovirus B19</article-title><source>JIACM</source><year>2005</year><volume>6</volume><fpage>319</fpage><lpage>326</lpage></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegl</surname><given-names>G</given-names></name><name><surname>Cassinotti</surname><given-names>P</given-names></name></person-group><article-title>Presence and significance of parvovirus B19 in blood and blood products</article-title><source>Biologicals</source><year>1998</year><volume>26</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1006/biol.1998.0138</pub-id><?supplied-pmid 9811511?><pub-id pub-id-type="pmid">9811511</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith-Whitley</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Hodinka</surname><given-names>R</given-names></name><etal/></person-group><article-title>Epidemiology of human parvovirus B19 in children with sickle cell disease</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>422</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-01-0069</pub-id><?supplied-pmid 14525777?><pub-id pub-id-type="pmid">14525777</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tello-Winniczuk</surname><given-names>N</given-names></name><name><surname>D&#x000ed;az-Jouanen</surname><given-names>E</given-names></name><name><surname>D&#x000ed;az-Borj&#x000f3;n</surname><given-names>A</given-names></name></person-group><article-title>Parvovirus B19&#x02013;associated arthritis</article-title><source>J Clin Rheumatol</source><year>2011</year><volume>17</volume><fpage>449</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1097/RHU.0b013e31823abf1a</pub-id><?supplied-pmid 22089996?><pub-id pub-id-type="pmid">22089996</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardeh</surname><given-names>A</given-names></name><name><surname>Marik</surname><given-names>P</given-names></name></person-group><article-title>Acute lung injury due to parvovirus pneumonia</article-title><source>J Intern Med</source><year>1998</year><volume>244</volume><fpage>257</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2796.1998.00364.x</pub-id><?supplied-pmid 9747749?><pub-id pub-id-type="pmid">9747749</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name></person-group><article-title>Parvovirus B19</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>586</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1056/NEJMra030840</pub-id><?supplied-pmid 14762186?><pub-id pub-id-type="pmid">14762186</pub-id></element-citation></ref></ref-list></back></article>